Nucleic Acid Extraction and Purification Market (2026-2036)

The growth of this market is mainly driven by the growth of next-generation sequencing (NGS) and molecular testing, which require high-quality DNA and RNA as the first step of every workflow; the expansion of oncology genomic testing and liquid biopsy, which requires extraction of nucleic acids from challenging samples such as formalin-fixed tissue and plasma cell-free DNA; the continued demand for molecular infectious disease testing and surveillance; and the increasing automation of sample preparation in clinical and high-throughput laboratories. In addition, the growth of single-cell, spatial, and long-read sequencing, the adoption of non-invasive samples such as saliva, urine, and stool, the expansion of genetic testing, biobanking, and population genomics, and the growing use of molecular methods in forensics, food, veterinary, and environmental testing are further supporting the growth of this market.

The Nucleic Acid Extraction and Purification Market, also referred to as the DNA and RNA extraction market, nucleic acid isolation and purification market, or sample preparation for molecular testing market, comprises the kits and reagents, instruments, and consumables used to isolate and purify DNA and RNA from biological and environmental samples for molecular analysis. The market includes manual extraction kits based on silica spin columns, magnetic beads, and solution-based chemistries; kits for genomic DNA, plasmid DNA, cell-free DNA, total RNA, microRNA, and viral and microbial nucleic acids; cleanup and size-selection reagents used in sequencing library preparation; automated extraction instruments ranging from low-throughput benchtop systems to high-throughput platforms and integrated workcells; and consumables such as cartridges, plates, tips, and magnetic particles. The market covers laboratory-scale extraction for research, clinical diagnostics, forensics, and applied testing, and excludes process-scale purification used in biopharmaceutical manufacturing. The market ecosystem extends from manufacturers of extraction chemistries, instruments, and consumables to academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, forensic laboratories, and food, agricultural, veterinary, and environmental testing laboratories.

Nucleic acid extraction is the first and often most critical step in molecular analysis. The yield, purity, and integrity of extracted DNA and RNA determine the success of downstream PCR, sequencing, microarray, and other analyses, and poor extraction can cause test failures, false negatives, or biased results. Because extraction is performed for every sample, demand for extraction products grows with the total volume of molecular testing, and kits and consumables provide recurring revenue tied to instrument installed bases.

Sequencing and molecular diagnostics are the main growth drivers. In the second quarter of 2026, Illumina, Inc. reported sequencing consumables revenue of USD 775 million, up 5% year over year, and sequencing instrument revenue of USD 125 million, up 31%, reflecting the continued growth of sequencing volumes that depend on upstream nucleic acid extraction and purification. Research applications such as whole-genome, exome, transcriptome, single-cell, and long-read sequencing require high-quality and, in some cases, high-molecular-weight DNA and intact RNA, and the growth of these applications is increasing demand for specialized extraction products. In late 2025, QIAGEN agreed to acquire Parse Biosciences, a provider of instrument-free single-cell sequencing tools, for up to USD 280 million, expanding its Sample technologies portfolio into single-cell sample preparation, with Parse expected to contribute approximately USD 40 million in sales in 2026.

Oncology and liquid biopsy are among the fastest-growing applications. In the second quarter of 2026, Tempus AI, Inc. reported 31% growth in oncology testing volume and 9,000 molecular residual disease tests, illustrating the rapid growth of tissue and liquid biopsy testing that requires extraction of DNA and RNA from formalin-fixed tissue and cell-free DNA from plasma. Extraction from formalin-fixed, paraffin-embedded (FFPE) tissue, which damages nucleic acids, and from plasma, which contains very small amounts of fragmented cell-free DNA, requires specialized chemistries and careful handling, and the growth of comprehensive genomic profiling, liquid biopsy, and molecular residual disease testing is driving demand for these products.

Infectious disease, genetic, and applied testing provide a broad and diversified base of demand. Molecular testing for respiratory, sexually transmitted, and hospital-acquired infections has remained well above pre-pandemic levels, and the large installed base of automated extraction systems placed during the COVID-19 pandemic continues to consume kits and cartridges. Genetic and reproductive testing, newborn and carrier screening, and population genomics programs extract DNA from blood and saliva at scale, while forensic laboratories, food safety and agricultural laboratories, veterinary laboratories, and environmental monitoring programs require extraction from evidence, food matrices, plants, animal samples, soil, and water. This diversity of applications makes extraction one of the most widely used product categories in molecular biology.

Automation is reshaping the market. Clinical and high-throughput laboratories are replacing manual extraction with automated systems to increase throughput, reduce hands-on time and errors, and improve reproducibility and traceability. In the second quarter of 2026, QIAGEN N.V. reported Sample technologies sales of USD 182 million, up 9% at constant exchange rates, with consumables growing at a high single-digit rate, automated consumables growing at a high-teens rate, and instruments growing at a mid-single-digit rate, while its next-generation QIAsymphony Connect platform generated strong customer interest, QIAsprint Connect received its first orders, and the compact QIAmini system remained on track for commercialization in the second half of 2026. Manufacturers are also developing compact systems for lower-throughput laboratories and integrated workflows linking extraction with PCR and sequencing library preparation.

The market includes leading life science and diagnostics companies such as QIAGEN, Thermo Fisher Scientific, Roche, Promega, Revvity, Danaher (through Beckman Coulter Life Sciences), Agilent Technologies, Merck KGaA, and Takara Bio, and specialized suppliers such as MACHEREY-NAGEL, Zymo Research, and New England Biolabs. These companies compete on yield and purity, performance with difficult samples, throughput and automation, compatibility with downstream assays, regulatory status for clinical use, cost per sample, and the size of their instrument installed bases.

At the same time, the market faces challenges, including the normalization of infectious disease testing volumes after the COVID-19 pandemic, price competition, particularly from manufacturers in China and other Asia-Pacific countries, the high cost of automated systems for smaller laboratories, the growing trend toward extraction-free and direct-to-PCR methods for some applications, and the variability of nucleic acid quality from challenging samples. As a result, companies that combine strong chemistries for difficult samples, scalable automation, integration with downstream workflows, regulatory-cleared clinical products, and competitive cost per sample are expected to capture the largest share of growth over the forecast period.